ITGAM and neoplasm: Many antineoplastic drugs studies had shown reduced proportion of CD11b+Gr-1+ cells in tumor-bearing mice after drug treatment (Fleming et al., 2018), in addition to lenvatinib (Gunda et al., 2019) and gemcitabine (Mu et al., 2019).